Sell Teva Pharmaceutical For -1.54% Loss On California Lawsuit
February 5, 2017: Sell Teva Pharmaceutical for a -1.54% loss. Sorry folks but better to get out for a small loss as not sure how big of penalties we’re looking at IF Teva is found guilty of actually doing what the State of California is saying they did but I’m thinking possibly hundreds of millions. The State of California filed in federal court in San Francisco allegations that Teva and Allergan had in place a “pay-for-delay” deal with Endo Pharmaceuticals between 2012 and 2014.
Lidoderm is the brand name for lidocaine transdermal patches, often prescribed for treatment of pain associated shingles.
The lawsuit claims that the unlawful agreement between the companies forced consumers to pay hundreds of millions of dollars in surpa-competitive prices for prescriptions of Lidoderm and generic equivalents from May 2012 until May 2014.
January 30, 2017: Teva Pharmaceutical Industries Ltd announced that the U.S. Food and Drug Administration (FDA) approved two products for adolescent and adult patients with asthma. These products, AirDuoTMRespiClick (fluticasone propionate and salmeterol inhalation powder) and ArmonAirTM RespiClick (fluticasone propionate inhalation powder), include medication delivered via Teva’s RespiClick breath-activated, multi-dose dry powder inhaler (MDPI) which is used with other approved medicines in Teva’s respiratory product portfolio.
AirDuoTM RespiClick is a fixed dose combination product containing the same active ingredients as Advair. AirDuo RespiClickis a corticosteroid and a long-acting beta2-adrenergic agonist (LABA) indicated for the treatment of asthma in patients aged 12 years and older. ArmonAirTM RespiClick® is an inhaled corticosteroid (ICS) containing the same active ingredient as Flovent, and is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years and older.
AirDuo RespiClick and ArmonAir RespiClick are expected to become available to patients in the U.S., by prescription, later this year. Both products have been approved in three strengths. The approved strengths of AirDuo RespiClick are: 55/14 mcg, 113/14 mcg and 232/14 mcg administered as one inhalation twice daily. The approved strengths of ArmonAir RespiClick are: 55 mcg, 113 mcg, and 232 mcg administered as one inhalation twice daily.
January 18, 2017: U.S. Food and Drug Administration (FDA) approved Teva Pharmaceutical’s VANTRELATM ER (hydrocodone bitartrate) extended-release tablets [CII] formulated with Teva’s proprietary abuse deterrence technology. VANTRELA ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The products approval is supported by a clinical program that evaluated the safety and efficacy of VANTRELA ER, as well as its abuse potential in laboratory-based in vitro manipulation and extraction studies, pharmacokinetic studies, and clinical abuse potential (CAP) studies.
January 9, 2017: Teva Pharmaceutical Industries CEO said, “…our migraine drug could create multiple billions in revenue.” The comment was made at the JP Morgan conference.
– Targeting 30% of the $8-12B migraine drug market
December 15, 2016: Teva Pharmaceutical Industries spokesperson says received complaint from state AGs regarding antitrust charges against generic drug makers; we are reviewing the complaint.
December 8, 2016: Teva Pharmaceutical Industries CEO said at a Citi conference that he expects 2017 to be a much better year for Teva.
December 5, 2016: Teva Pharmaceutical announced that it had received a positive outcome through the variation procedure to remove the pregnancy contraindication from the European label for COPAXONE(glatiramer acetate injection) 20 mg/mL. The product was originally authorized through a decentralized procedure in Europe.
The removal of the pregnancy contraindication follows a Positive Variation Assessment Report issued by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA; Reference Member State), and agreed by all Concerned Member States (CMS) in Europe, that were involved in the procedure. Granting of governmental approvals by all involved EU Member States will happen shortly. COPAXONEis indicated for the treatment of patients with relapsing forms of multiple sclerosis (RMS).
The removal of the contraindication is based on a comprehensive examination of available prospective pregnancy cases with known outcome and confirmed exposure to COPAXONE. A supporting analysis was also provided comparing data from Teva’s Glatiramer Acetate (GA) Pharmacovigilance Database which captured more than 8,000 pregnancies over a period of more than 20 years.
December 5, 2016: Teva Pharmaceutical announced that Dipankar Bhattacharjee had been appointed President and Chief Executive Officer, Global Generic Medicines Group, effective today. Mr. Bhattacharjee, who has served as President and CEO of Teva Generics Europe since April 2013, succeeds Sigurdur (Siggi) Olafsson, who will step down from his role and remain active with the Company until officially retiring at the end of the first quarter of 2017 to ensure an orderly transition. Mr. Bhattacharjee will be based in the U.S.
As President and CEO of Teva Generics Europe, Mr. Bhattacharjee has a proven track record of improving revenues and profitability, significantly increasing operating profit margins in the European generics business. Under his leadership, Tevas European business demonstrated consistent improvement in sales and profits, establishing Teva as one of the premier generics companies in Europe. He has focused on improving and enhancing the European generics operations, leading a full European integration of Actavis Generics and overseeing successful new product launches.
In conjunction with today’s announcement, Teva is reaffirming its full-year 2016 outlook. Revenues for the full year 2016 are expected to be $21.6-$21.9 billion and revenues for the fourth quarter of the year 2016 are projected to be $6.2-$6.5 billion. Non-GAAP EPS for 2016 is expected to be $5.10-$5.20, based on a weighted average number of shares of 1,020 million; non-GAAP EPS is projected to be $1.34-$1.44, based on a weighted average number of shares of 1,077 million. Cash flow from operating activities for 2016 is expected to be $4.8-$5.0 billion; cash flow from operating activities for the fourth quarter of 2016 is expected to be $1.0-$1.2 billion.
November 30, 2016: Hearing vague takeover chatter circulating about Teva. Teva has a market cap of $35 billion so it would be hard to keep a deal of that size quiet for long. It seems takeover rumors are always circulating. I can’t track down the source of the rumors, and so I’m skeptical about them for now. Will keep following the rumors and update you on any substantive information.
Teva Pharmaceutical Stock Chart
The Finviz screener settings used to find Teva Pharmaceutical’s are: Sector Healthcare, Forward P/E Under 10, EPS growth qtr over qtr Over 30%, Gross Margin High (>50%)
Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.
Teva was established in 1901. Our global headquarters are based in Israel.
Today we have a portfolio of more than 1,000 molecules, producing approximately 64 billion tablets and capsules a year at 66 manufacturing facilities.
We rank among the 10 top pharmaceutical companies in the world and are active in 60 countries. Approximately 58,000 employees around the world are dedicated to our mission.
Latest posts by Lance Jepsen (see all)
- S&P 500 Index Does Breakout, 2500 Next - May 28, 2017
- IMAX Theaters Goes Into Virtual Reality as M&A Talk Picks Up - May 28, 2017
- How High Bitcoin Go 2017, Many Say $10,000 - May 28, 2017